Westlake Village, California, United States
Transformational commercial executive with 25+ years of enterprise leadership across Immunology, Dermatology, Rheumatology, and Gastroenterology. I build world-class commercial organizations, launch first-in-class therapies, and drive sustained top- and bottom-line performance at scale. Throughout my career I have led commercial organizations from the ground up, executed landmark product launches, and guided companies through pivotal inflection points from high-growth expansion to comprehensive commercial turnarounds. My experience spans full P&L accountability, global go-to-market strategy, payer and market access, executive talent development, and digital commercial transformation. Current: EVP & Chief Commercial Officer, Arcutis Biotherapeutics Recruited to lead a commercial transformation following an underperforming launch, I pivoted the organization's strategy, rebuilt the leadership team, executed multiple product launches, and delivered consistent sequential quarter-over-quarter revenue growth establishing Arcutis as a commercially credible and competitive dermatology company. Career Highlights: • Launched the first topical JAK inhibitor for atopic dermatitis and the first FDA-approved re-pigmentation treatment for vitiligo (Incyte) • Meaningfully scaled UCB U.S. Immunology net sales across Rheumatology, Dermatology, and Gastroenterology • Built two dermatology business units from inception with full P&L accountability • Led global immunology operations and strategy across international markets (UCB, Brussels) • Progressed from sales representative to C-suite across industry-leading organizations U.S. Army veteran. Bronze Star Medal recipient. MBA, Embry-Riddle Aeronautical University.
Recruited to lead a comprehensive commercial transformation, I pivoted the organization's go-to-market strategy, restructured the commercial leadership team, and installed the right talent in key roles to restore market confidence and drive sustainable momentum. • Successfully executed multiple product launches within the dermatology portfolio, applying rigorous launch discipline, cross-functional alignment, and market-specific strategies to accelerate commercial uptake and brand performance. • Delivered consistent sequential quarter-over-quarter net revenue growth, establishing a durable and accelerating performance trajectory. • Architected and deployed highly innovative commercial solutions that meaningfully differentiated the company's product offerings in a competitive dermatology market. • Established Arcutis as a commercially credible and strategically agile dermatology organization, positioning the company for sustained long-term market leadership.
Provided executive leadership, strategic vision, and functional expertise to build Incyte's dermatology business unit and deliver two landmark first-in-class product launches. • Architected and launched a fully integrated dermatology business unit from inception, establishing infrastructure, talent, and go-to-market capabilities to support two landmark product introductions. • Orchestrated the successful U.S. commercial launch of the first and only topical JAK inhibitor approved for atopic dermatitis, and the first and only FDA-approved treatment for re-pigmentation of vitiligo. • Designed and executed a comprehensive payer and retail distribution strategy within ten months post-launch, rapidly accelerating NDC block removals, paid claims, and a favorable gross-to-net profile. • Established Incyte as a recognized and trusted dermatology company through strategic stakeholder engagement, medical education, and customer-facing excellence. • Full P&L accountability; defined revenue and profitability targets in alignment with executive leadership.
Served as the strategic and operational backbone of UCB's global immunology business unit, accountable for portfolio delivery, resource prioritization, and enterprise-wide execution across international markets. • Directed global immunology product launch strategy and end-to-end lifecycle management across Rheumatology, Dermatology, and Gastroenterology. • Partnered with Corporate Business Development and Alliance Management to identify and assess portfolio expansion opportunities. • Spearheaded a company-wide digital go-to-market transformation, enabling adjacent and transformative platform initiatives across commercial and medical functions. • Established financial frameworks and cross-functional governance processes to optimize business impact and resource allocation.
Led a world-class U.S. commercial organization supporting an injectable biologic portfolio and robust pipeline across Rheumatology, Dermatology, and Gastroenterology. Full P&L accountability. • Delivered sustained top-line performance, growing business unit net sales while consistently exceeding annual plan commitments. • Successfully launched PsA, AS, and nr-AxSpA indications within Rheumatology, and established the organization as a credible and trusted dermatology partner ahead of the PSO launch. • Built commercial infrastructure, launch capabilities, and high-performing teams from the ground up. • Routinely exceeded annual net sales targets across the full tenure of the role.